HABA Laboratories,Inc. Logo

HABA Laboratories,Inc.

4925.T

(1.5)
Stock Price

1.841,00 JPY

-15.98% ROA

-20.91% ROE

-3.79x PER

Market Cap.

7.294.550.151,00 JPY

25.55% DER

2.07% Yield

-15.5% NPM

HABA Laboratories,Inc. Stock Analysis

HABA Laboratories,Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

HABA Laboratories,Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.8x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (19%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

4 Dividend

The company has consistently provided dividends over the past three years, indicating a reliable source of income for investors.

5 ROE

Negative ROE (-5.2%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-3.96%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

9 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

10 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-20.281) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

HABA Laboratories,Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

HABA Laboratories,Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

HABA Laboratories,Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

HABA Laboratories,Inc. Revenue
Year Revenue Growth
2007 11.042.840.000
2008 11.182.798.000 1.25%
2009 11.318.015.000 1.19%
2010 11.809.979.000 4.17%
2011 13.578.544.000 13.02%
2012 13.233.767.000 -2.61%
2013 13.786.971.000 4.01%
2014 13.181.178.000 -4.6%
2015 14.811.078.000 11%
2016 16.135.567.000 8.21%
2017 17.885.688.000 9.79%
2018 19.253.557.000 7.1%
2019 18.369.640.000 -4.81%
2020 14.307.709.000 -28.39%
2021 12.908.861.000 -10.84%
2022 12.038.052.000 -7.23%
2023 11.461.508.000 -5.03%
2023 12.324.210.000 7%
2024 10.683.344.000 -15.36%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

HABA Laboratories,Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 224.000.000 100%
2013 263.000.000 14.83%
2014 247.000.000 -6.48%
2015 224.686.000 -9.93%
2016 218.214.000 -2.97%
2017 213.501.000 -2.21%
2018 170.552.000 -25.18%
2019 150.214.000 -13.54%
2020 148.949.000 -0.85%
2021 152.565.000 2.37%
2022 176.400.000 13.51%
2023 0 0%
2023 125.108.000 100%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

HABA Laboratories,Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 4.435.000.000 100%
2013 4.328.000.000 -2.47%
2014 4.280.000.000 -1.12%
2015 4.362.560.000 1.89%
2016 4.600.349.000 5.17%
2017 4.889.251.000 5.91%
2018 4.918.808.000 0.6%
2019 5.322.846.000 7.59%
2020 4.438.252.000 -19.93%
2021 4.332.989.000 -2.43%
2022 4.338.290.000 0.12%
2023 0 0%
2023 4.297.724.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

HABA Laboratories,Inc. EBITDA
Year EBITDA Growth
2007 1.162.148.000
2008 1.406.819.000 17.39%
2009 1.412.215.000 0.38%
2010 1.159.901.000 -21.75%
2011 1.716.948.000 32.44%
2012 1.094.176.000 -56.92%
2013 1.903.304.000 42.51%
2014 881.859.000 -115.83%
2015 2.193.366.000 59.79%
2016 2.312.427.000 5.15%
2017 3.024.618.000 23.55%
2018 3.724.525.000 18.79%
2019 2.612.780.000 -42.55%
2020 926.907.000 -181.88%
2021 422.668.000 -119.3%
2022 -16.911.000 2599.37%
2023 -440.056.000 96.16%
2023 331.501.000 232.75%
2024 -17.032.000 2046.34%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

HABA Laboratories,Inc. Gross Profit
Year Gross Profit Growth
2007 8.637.379.000
2008 8.757.213.000 1.37%
2009 9.039.505.000 3.12%
2010 9.599.099.000 5.83%
2011 10.148.347.000 5.41%
2012 9.828.946.000 -3.25%
2013 10.477.394.000 6.19%
2014 9.976.076.000 -5.03%
2015 11.182.844.000 10.79%
2016 12.112.565.000 7.68%
2017 13.338.930.000 9.19%
2018 14.512.660.000 8.09%
2019 13.664.205.000 -6.21%
2020 10.199.950.000 -33.96%
2021 8.794.810.000 -15.98%
2022 8.168.522.000 -7.67%
2023 7.928.020.000 -3.03%
2023 8.026.063.000 1.22%
2024 7.081.472.000 -13.34%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

HABA Laboratories,Inc. Net Profit
Year Net Profit Growth
2007 299.831.000
2008 393.361.000 23.78%
2009 266.498.000 -47.6%
2010 22.127.000 -1104.4%
2011 537.865.000 95.89%
2012 10.052.000 -5250.83%
2013 916.354.000 98.9%
2014 44.834.000 -1943.88%
2015 982.403.000 95.44%
2016 1.213.611.000 19.05%
2017 1.597.847.000 24.05%
2018 2.088.478.000 23.49%
2019 1.313.475.000 -59%
2020 216.419.000 -506.91%
2021 -269.030.000 180.44%
2022 -707.865.000 61.99%
2023 -360.224.000 -96.51%
2023 -2.118.627.000 83%
2024 -88.984.000 -2280.91%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

HABA Laboratories,Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 91
2008 100 8.08%
2009 68 -47.76%
2010 6 -1240%
2011 137 96.32%
2012 3 -6700%
2013 233 99.14%
2014 11 -2009.09%
2015 250 95.58%
2016 308 19.16%
2017 406 23.95%
2018 531 23.58%
2019 339 -56.34%
2020 57 -494.74%
2021 -71 180.28%
2022 -187 62.03%
2023 -95 -96.84%
2023 -560 83.04%
2024 -24 -2334.78%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

HABA Laboratories,Inc. Free Cashflow
Year Free Cashflow Growth
2007 -893.166.000
2008 679.051.000 231.53%
2009 -519.943.000 230.6%
2010 -104.902.000 -395.65%
2011 118.716.000 188.36%
2012 1.222.622.000 90.29%
2013 637.399.000 -91.81%
2014 -407.206.000 256.53%
2015 1.139.038.000 135.75%
2016 464.625.000 -145.15%
2017 1.780.560.000 73.91%
2018 1.448.972.000 -22.88%
2019 -234.465.000 717.99%
2020 -346.946.000 32.42%
2021 1.526.942.000 122.72%
2022 -232.694.000 756.2%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

HABA Laboratories,Inc. Operating Cashflow
Year Operating Cashflow Growth
2007 272.200.000
2008 975.563.000 72.1%
2009 362.591.000 -169.05%
2010 411.546.000 11.9%
2011 682.490.000 39.7%
2012 1.521.915.000 55.16%
2013 1.540.149.000 1.18%
2014 -178.754.000 961.6%
2015 1.907.071.000 109.37%
2016 1.495.317.000 -27.54%
2017 2.670.956.000 44.02%
2018 1.921.810.000 -38.98%
2019 675.509.000 -184.5%
2020 534.710.000 -26.33%
2021 1.714.447.000 68.81%
2022 55.956.000 -2963.92%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

HABA Laboratories,Inc. Capital Expenditure
Year Capital Expenditure Growth
2007 1.165.366.000
2008 296.512.000 -293.02%
2009 882.534.000 66.4%
2010 516.448.000 -70.89%
2011 563.774.000 8.39%
2012 299.293.000 -88.37%
2013 902.750.000 66.85%
2014 228.452.000 -295.16%
2015 768.033.000 70.25%
2016 1.030.692.000 25.48%
2017 890.396.000 -15.76%
2018 472.838.000 -88.31%
2019 909.974.000 48.04%
2020 881.656.000 -3.21%
2021 187.505.000 -370.2%
2022 288.650.000 35.04%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

HABA Laboratories,Inc. Equity
Year Equity Growth
2007 4.900.451.000
2008 5.271.611.000 7.04%
2009 5.351.214.000 1.49%
2010 5.286.939.000 -1.22%
2011 5.725.216.000 7.66%
2012 5.658.485.000 -1.18%
2013 6.498.628.000 12.93%
2014 6.466.908.000 -0.49%
2015 7.368.628.000 12.24%
2016 8.503.763.000 13.35%
2017 9.983.955.000 14.83%
2018 11.951.676.000 16.46%
2019 11.972.893.000 0.18%
2020 12.039.071.000 0.55%
2021 11.637.668.000 -3.45%
2022 10.773.645.000 -8.02%
2023 8.507.097.000 -26.64%
2023 11.257.765.000 24.43%
2024 8.334.401.000 -35.08%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

HABA Laboratories,Inc. Assets
Year Assets Growth
2007 10.482.760.000
2008 11.425.435.000 8.25%
2009 12.354.507.000 7.52%
2010 12.640.350.000 2.26%
2011 14.728.984.000 14.18%
2012 13.647.087.000 -7.93%
2013 13.956.191.000 2.21%
2014 13.162.306.000 -6.03%
2015 12.788.493.000 -2.92%
2016 13.512.452.000 5.36%
2017 15.240.536.000 11.34%
2018 16.494.073.000 7.6%
2019 17.091.438.000 3.5%
2020 17.441.060.000 2%
2021 15.685.434.000 -11.19%
2022 14.655.217.000 -7.03%
2023 12.431.193.000 -17.89%
2023 15.213.749.000 18.29%
2024 12.056.659.000 -26.19%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

HABA Laboratories,Inc. Liabilities
Year Liabilities Growth
2007 5.582.309.000
2008 6.153.824.000 9.29%
2009 7.003.293.000 12.13%
2010 7.353.411.000 4.76%
2011 9.003.768.000 18.33%
2012 7.988.602.000 -12.71%
2013 7.457.563.000 -7.12%
2014 6.695.398.000 -11.38%
2015 5.419.865.000 -23.53%
2016 5.008.689.000 -8.21%
2017 5.256.581.000 4.72%
2018 4.542.397.000 -15.72%
2019 5.118.545.000 11.26%
2020 5.401.989.000 5.25%
2021 4.047.766.000 -33.46%
2022 3.881.572.000 -4.28%
2023 3.924.095.000 1.08%
2023 3.955.984.000 0.81%
2024 3.722.257.000 -6.28%

HABA Laboratories,Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3285.82
Net Income per Share
-509.27
Price to Earning Ratio
-3.79x
Price To Sales Ratio
0.59x
POCF Ratio
9.79
PFCF Ratio
9.79
Price to Book Ratio
0.88
EV to Sales
0.46
EV Over EBITDA
15.36
EV to Operating CashFlow
7.65
EV to FreeCashFlow
7.65
Earnings Yield
-0.26
FreeCashFlow Yield
0.1
Market Cap
7,29 Bil.
Enterprise Value
5,70 Bil.
Graham Number
5025.4
Graham NetNet
699.24

Income Statement Metrics

Net Income per Share
-509.27
Income Quality
-0.35
ROE
-0.21
Return On Assets
-0.16
Return On Capital Employed
0.01
Net Income per EBT
1.22
EBT Per Ebit
-23.99
Ebit per Revenue
0.01
Effective Tax Rate
-0.22

Margins

Sales, General, & Administrative to Revenue
-0.14
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.68
Operating Profit Margin
0.01
Pretax Profit Margin
-0.13
Net Profit Margin
-0.15

Dividends

Dividend Yield
0.02
Dividend Yield %
2.07
Payout Ratio
0
Dividend Per Share
40

Operating Metrics

Operating Cashflow per Share
196.95
Free CashFlow per Share
196.95
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.01
Return on Tangible Assets
-0.16
Days Sales Outstanding
31.03
Days Payables Outstanding
32.51
Days of Inventory on Hand
337.59
Receivables Turnover
11.76
Payables Turnover
11.23
Inventory Turnover
1.08
Capex per Share
0

Balance Sheet

Cash per Share
986,01
Book Value per Share
2.203,98
Tangible Book Value per Share
2201.99
Shareholders Equity per Share
2203.98
Interest Debt per Share
566.19
Debt to Equity
0.26
Debt to Assets
0.18
Net Debt to EBITDA
-4.31
Current Ratio
3.18
Tangible Asset Value
8,33 Bil.
Net Current Asset Value
4,97 Bil.
Invested Capital
8907258000
Working Capital
5,96 Bil.
Intangibles to Total Assets
0
Average Receivables
1,16 Bil.
Average Payables
0,33 Bil.
Average Inventory
3702177500
Debt to Market Cap
0.29

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

HABA Laboratories,Inc. Dividends
Year Dividends Growth
2004 20
2008 20 0%
2010 20 0%
2011 20 0%
2012 20 0%
2013 20 0%
2014 20 0%
2015 20 0%
2016 20 0%
2017 30 33.33%
2018 30 0%
2019 40 25%
2020 40 0%
2021 40 0%
2022 40 0%
2023 40 0%
2024 40 0%
2025 0 0%

HABA Laboratories,Inc. Profile

About HABA Laboratories,Inc.

HABA Laboratories,Inc. manufactures and sells skin care, and hair and body care products in Japan and internationally. Its skin care products include cleansers/face washes, toners, special care products, and squalane oils; and hair and body care products comprise shampoos, conditioners, soaps, and hair and hand treatment products. The company sells its products through mail order, shops, drug/variety stores, and internet. It has approximately 70 HABA shops located in department stores, shopping malls, etc. HABA Laboratories,Inc. was founded in 1983 and is headquartered in Tokyo, Japan.

CEO
Issei Miyazaki
Employee
631
Address
1-24-11, Kanda Sudacho
Tokyo, 101-0041

HABA Laboratories,Inc. Executives & BODs

HABA Laboratories,Inc. Executives & BODs
# Name Age
1 Ms. Noriko Koyanagi
Executive Chairman
70
2 Issei Miyazaki
President, Chief Executive Officer, MD & Director
70
3 Yoshinori Nishimura
In charge of Food Dev., Quality Assu., Corporation Planning, Design & Corp. Sales Department and Director
70

HABA Laboratories,Inc. Competitors

Akatsuki Inc. Logo
Akatsuki Inc.

3932.T

(3.0)
Fancl Corporation Logo
Fancl Corporation

4921.T

(2.0)
WIN-Partners Co., Ltd. Logo
WIN-Partners Co., Ltd.

3183.T

(2.0)
AJIS Co., Ltd. Logo
AJIS Co., Ltd.

4659.T

(2.2)
Qol Holdings Co., Ltd. Logo
Qol Holdings Co., Ltd.

3034.T

(2.0)